Mounjaro beats Wegovy on average weight loss in published trials — 20.9% of body weight versus 14.9% — and Zepbound, the third name in this search, isn't sold in the UAE at all. It's the same tirzepatide molecule as Mounjaro, just marketed under a US-only brand name. This page benchmarks all three by trial data, dosing schedule, and regulatory status so you know exactly what you're comparing before starting a program in 2026.
TL;DR- Mounjaro (tirzepatide) averaged 20.9% weight loss at 72 weeks versus Wegovy's 14.9% at 68 weeks.
- Zepbound is a US-only brand for tirzepatide — it is not registered or sold in the UAE in 2026.
- Ask for Mounjaro if you're looking for what Zepbound offers; same molecule, same titration schedule.
- Mounjaro and Wegovy are both DHA/DoH approved for weight management in the UAE.
- Comparing mounjaro vs wegovy vs zepbound uae comes down to mechanism, dose ceiling, and what's actually on the shelf.
Why this matters
Patients searching "mounjaro vs wegovy vs zepbound uae" are usually comparing three names for what's really two drugs. Tirzepatide and semaglutide are the active molecules; Mounjaro, Wegovy, and Zepbound are the commercial names attached to them in different markets. Getting the brand-to-molecule mapping wrong means asking a UAE pharmacist for something that was never registered there.
DarDoc runs its at-home GLP-1 program under doctor-reviewed protocols, with a licensed physician setting the dose and a nurse handling injection administration and follow-up blood work at home. That structure only works if the drug itself is approved for the indication you're using it for — which is where the regulatory table below matters more than the marketing.
Average weight loss by drug (clinical trial data)
The average weight loss reported for tirzepatide-based therapy (Mounjaro, and Zepbound where it's sold) is 20.9% of body weight at 72 weeks. Semaglutide-based therapy (Wegovy) averages 14.9% at 68 weeks. Both figures come from each drug's pivotal Phase 3 trial, not from marketing copy.
| Drug (brand) | Active ingredient | Pivotal trial | Duration | Average weight loss |
|---|---|---|---|---|
| Mounjaro | Tirzepatide | SURMOUNT-1 | 72 weeks | 20.9% (15mg dose) |
| Zepbound | Tirzepatide (same molecule, US brand) | SURMOUNT-1 | 72 weeks | 20.9% (15mg dose) |
| Wegovy | Semaglutide | STEP 1 | 68 weeks | 14.9% (2.4mg dose) |
| Category average | — | — | — | 17.9% |
Tirzepatide-based therapy leads at 20.9%; semaglutide-based therapy trails at 14.9% — a gap of roughly 6 percentage points of body weight at trial end. That gap tracks the mechanism: tirzepatide activates both the GIP and GLP-1 receptors, while semaglutide activates GLP-1 alone.
These numbers are the placebo-adjusted mean weight loss reported in SURMOUNT-1 (tirzepatide, published in the New England Journal of Medicine, 2022) and STEP 1 (semaglutide, NEJM, 2021), both in adults with obesity or overweight without diabetes. The limitation worth naming: trial participants were closely monitored under research protocols with structured follow-up, so unsupervised or inconsistent dosing in real-world use tends to produce lower averages than these figures.
Dosing and administration benchmarks
All three drugs are once-weekly injections that start low and step up over roughly four-week intervals — the difference is the ceiling dose, not the delivery method.
| Drug | Starting dose | Maintenance dose studied | Frequency | Titration interval |
|---|---|---|---|---|
| Mounjaro | 2.5mg | 15mg | Weekly injection | ~4 weeks per step |
| Zepbound | 2.5mg | 15mg | Weekly injection | ~4 weeks per step (US only) |
| Wegovy | 0.25mg | 2.4mg | Weekly injection | ~4 weeks per step |
Mounjaro and Wegovy share an almost identical injection rhythm; the real variable is tolerance during the climb to maintenance dose, not how often you inject. Gastrointestinal side effects — nausea, reduced appetite, occasional constipation — cluster around each dose increase for both drugs, which is why UAE clinicians titrate on a schedule rather than pushing to maintenance dose quickly.
Regulatory and brand availability in the UAE
This is the part most comparison searches miss: two of these three names are on UAE shelves, and one isn't.
| Drug | Active ingredient | DHA/DoH approval status | Sold in UAE pharmacies |
|---|---|---|---|
| Mounjaro | Tirzepatide | Approved for weight management | Yes |
| Wegovy | Semaglutide | Approved for weight management | Yes |
| Zepbound | Tirzepatide (US brand) | Not registered in the UAE | No — Mounjaro carries the same molecule |
Mounjaro and Wegovy both carry regulatory approval and sit on UAE pharmacy shelves in 2026; Zepbound doesn't exist as a UAE product at all. Eli Lilly markets the same tirzepatide molecule there exclusively under the Mounjaro name.
“Zepbound and Mounjaro are the same drug under two different brand names — only one of them is sold in the UAE.”
That distinction matters for anyone starting a program through a licensed home healthcare provider in Dubai: a provider offering "Zepbound" in the UAE isn't offering a registered product, full stop.
Start a doctor-reviewed GLP-1 program
DHA/DoH-licensed physicians set the dose; nurses handle injections at home.
Book a consultationHow to use these benchmarks
- If maximum average weight loss is the priority, tirzepatide (Mounjaro) at 20.9% outperforms semaglutide (Wegovy) at 14.9% in trial data — ask your physician whether you're a candidate for the higher-dose protocol.
- If you came looking for "Zepbound" because of US marketing, the UAE equivalent runs under the Mounjaro name — same molecule, same 4-week titration rhythm.
- Confirm DHA/DoH approval status before starting any GLP-1 or GIP/GLP-1 therapy through a provider — see the full Mounjaro cost breakdown for the UAE for what dose-by-dose pricing actually looks like in 2026.
- Choose based on your own tolerance for titration-phase side effects, not just the headline average-weight-loss number — trial averages hide a wide range of individual response.
FAQ
Is Zepbound available in the UAE?
No. Zepbound is Eli Lilly's US-only brand name for tirzepatide. In the UAE, the same tirzepatide molecule is sold and prescribed under DHA/DoH-approved protocols as Mounjaro in 2026.
Which is more effective, Mounjaro or Wegovy?
Mounjaro (tirzepatide) produced 20.9% average weight loss at 72 weeks in the SURMOUNT-1 trial, versus 14.9% for Wegovy (semaglutide) at 68 weeks in STEP 1. Individual response still varies by patient.
What's the actual difference between tirzepatide and semaglutide?
Tirzepatide activates both the GIP and GLP-1 receptors, while semaglutide activates GLP-1 only. That dual mechanism is the reason tirzepatide-based therapy shows a higher average weight loss in trials.
How long does titration take for Mounjaro or Wegovy?
Both drugs step up in roughly four-week intervals, moving from a low starting dose (2.5mg for Mounjaro, 0.25mg for Wegovy) to the maintenance range over several months under physician supervision.
Are Mounjaro and Wegovy DHA/DoH approved in the UAE?
Yes. Both carry regulatory approval for weight management in the UAE as of 2026 and are dispensed through licensed pharmacies and clinicians.
What does Mounjaro cost in the UAE?
Cost depends on the dose and program length, not a single flat figure. Check a current, itemized cost breakdown before comparing it to any other drug's price.
What side effects should you expect when starting?
Nausea, reduced appetite, and mild gastrointestinal upset are the most commonly reported effects during dose titration for both tirzepatide and semaglutide, based on their respective trial data.
Does weight return after stopping Mounjaro or Wegovy?
Trial follow-up data for both drug classes shows most patients regain a portion of lost weight after discontinuation, which is why UAE clinicians treat these as long-term managed programs rather than short courses.
One last thing
The detail almost every comparison search skips: Zepbound exists as a separate brand name in the US largely because Eli Lilly needed tirzepatide to carry a distinct label and pricing code for the weight-management indication, apart from Mounjaro's diabetes indication. That US-specific labeling split has no equivalent in the UAE — there's one brand, one approval, one name to ask for. If you're comparing mounjaro vs wegovy vs zepbound uae in 2026, drop Zepbound from the list entirely and compare Mounjaro against Wegovy on the numbers that actually apply here.
